Compare Arista Networks Inc (ANET) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Arista Networks Inc vs Ascendis Pharma A/S — how do they compare? Arista Networks Inc trades at $210.75 (market cap $249.53B), while Ascendis Pharma A/S trades at $254.7 (market cap $16.67B). The key difference: Arista Networks Inc is far larger — about 15× Ascendis Pharma A/S's market cap, and Arista Networks Inc is trading nearer its 52-week high, Ascendis Pharma A/S nearer its low. Which is the better fit depends on your goals.
| ANET | ASND | |
|---|---|---|
Market Cap | $249.53B | $16.67B |
Sector | Technology | Health |
52-Week High | $197.85 | $277.18 |
52-Week Low | $116.13 | $189.74 |
Enterprise Value | $236.19B | $17.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Arista Networks (ANET) trades at $208.47, up 8.85% in the last session, reflecting strong momentum amid robust AI-driven demand. The stock shows bullish technical signals with consistent earnings beats and accelerating revenue growth, reaching $9.01B in 2025. Analyst consensus remains overwhelmingly positive with a $252.25 price target, though valuation multiples appear elevated at P/E 62.61 and P/S 23.94. Recent news highlights insider selling but maintains confidence in the company's AI networking leadership.
Outlook remains favorable given hyperscaler capex expansion and Ethernet market share gains, but risks include premium valuation compression and competitive pressures. The stock offers growth exposure to AI infrastructure with solid execution, though investors should weigh high expectations against potential volatility.
Ascendis Pharma (ASND) trades at $255.17, down slightly by 0.18% on the day, while maintaining strong analyst support with 92% buy ratings and a $309.75 consensus price target. The company shows impressive revenue growth from $51M in 2022 to $720M in 2025, with profitability improving as net loss narrows to -$228M. Recent technical indicators show a bullish trend with the stock trading near resistance at $255-257, while fundamental metrics reveal high valuation ratios (P/E 29.05, P/S 15.68) offset by exceptional gross margins of 89.04%.
ASND presents a compelling growth story with multiple product launches in rare endocrine diseases driving revenue expansion, though investors face risks from negative shareholder equity and high debt levels. The company's transition to positive operating cash flow ($54M in 2025) and inclusion in Russell indexes signal maturation, but execution risks remain as the stock trades at premium valuations requiring continued strong performance to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Arista Networks Inc
Arista Networks is a software and hardware provider for the networking solutions sector. Operating as one business unit, software, switching, and router products are targeted for high-performance networking applications, while service revenue comes from technical support. Customer markets include data centers, enterprises, service providers, and campuses. The company is headquartered in Santa Clara, California, and generates most of its revenue in the Americas.
Read more on ANET →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
